BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts give BioNTech (BNTX) a consensus recommendation of Moderate Buy from 18 firms (1 sell, 4 hold, 12 buy, 1 strong buy) with an average 12‑month price target of $133.13.
• Shares opened at $95.50, the company has a market cap of $24.0B, a 12‑month range of $79.52–$124.00 and a negative trailing P/E of -18.23; BioNTech reported quarterly EPS of ($0.39) and analysts forecast -3.88 EPS for the fiscal year.
• Institutional investors have materially increased exposure—Dodge & Cox boosted its stake by 315.7% to 3.65M shares and GSK initiated a ~$84.7M position—leaving institutions with about 15.52% ownership.

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eighteen research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, twelve have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $133.1333.

BNTX has been the subject of a number of recent research reports. Raymond James Financial reiterated an "outperform" rating on shares of BioNTech in a research report on Tuesday, March 10th. Bank of America restated a "buy" rating and issued a $128.00 target price on shares of BioNTech in a report on Tuesday, March 10th. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating on shares of BioNTech in a research report on Tuesday, March 17th. Canaccord Genuity Group reiterated a "buy" rating and issued a $171.00 price target on shares of BioNTech in a research report on Wednesday, March 11th. Finally, Berenberg Bank reiterated a "buy" rating on shares of BioNTech in a research report on Friday, January 23rd.

BioNTech Stock Performance

Shares of BNTX opened at $95.50 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.49. The firm's 50 day moving average is $98.81 and its 200-day moving average is $101.02. BioNTech has a 12-month low of $79.52 and a 12-month high of $124.00. The stock has a market capitalization of $24.00 billion, a P/E ratio of -18.23 and a beta of 1.58.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its earnings results on Saturday, February 14th. The company reported ($0.39) EPS for the quarter. The business had revenue of $1.06 billion for the quarter. BioNTech had a negative net margin of 38.09% and a negative return on equity of 4.76%. Equities research analysts anticipate that BioNTech will post -3.88 EPS for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Hedge funds and other institutional investors have recently modified their holdings of the stock. Dodge & Cox lifted its position in shares of BioNTech by 315.7% in the 3rd quarter. Dodge & Cox now owns 3,647,091 shares of the company's stock valued at $359,676,000 after acquiring an additional 2,769,654 shares in the last quarter. GSK plc purchased a new stake in shares of BioNTech in the 4th quarter valued at approximately $84,711,000. BNP Paribas Financial Markets lifted its position in shares of BioNTech by 43.0% in the 4th quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company's stock valued at $150,235,000 after acquiring an additional 474,796 shares in the last quarter. Bank of America Corp DE raised its position in BioNTech by 344.4% during the third quarter. Bank of America Corp DE now owns 573,356 shares of the company's stock valued at $56,544,000 after buying an additional 444,332 shares during the period. Finally, Voloridge Investment Management LLC acquired a new position in BioNTech during the fourth quarter valued at $41,656,000. Institutional investors and hedge funds own 15.52% of the company's stock.

About BioNTech

BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.